Compare Cytokinetics Inc (CYTK) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Gartner Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Gartner Inc trades at $191.18 (market cap $12.34B). The key difference: Gartner Inc is the larger of the two by market cap, and Gartner Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Gartner Inc for 64 Days on average.
| CYTK | IT | |
|---|---|---|
Market Cap | $8.62B | $12.34B |
Volume | 2,594,626 | 919,809 |
Sector | Health | Technology |
52-Week High | $87.26 | $258.17 |
52-Week Low | $54.76 | $125.68 |
Typical Hold Time | 19 Days | 64 Days |
Enterprise Value | $8.72B | $14.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Gartner (IT) trades at $191.15, up 2.9% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 69.63% gross margins, and 113.58% ROE. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium. Cash flow trends show operational strength despite negative net cash flow in 2025.
Outlook remains positive with AI-driven consulting demand supporting growth, though risks include shareholder investigation and competitive pressures. Analyst consensus at $174.63 suggests caution despite 27.78% buy ratings. The stock's high P/B ratio of 160.06 warrants monitoring for valuation sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
